Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITOS NASDAQ:OCUL NASDAQ:SNDX NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITOSiTeos Therapeutics$10.15$10.14$6.18▼$11.35$448.73M1.311.57 million shsN/AOCULOcular Therapeutix$8.23+0.1%$8.81$6.23▼$16.44$1.80B0.932.89 million shs2.03 million shsSNDXSyndax Pharmaceuticals$19.94+0.9%$22.64$8.59▼$25.59$1.77B0.411.78 million shs1.15 million shsVCELVericel$34.73-1.2%$33.72$28.95▼$45.97$1.77B1.15710,587 shs383,195 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITOSiTeos Therapeutics0.00%0.00%0.00%0.00%+23.48%OCULOcular Therapeutix0.00%-10.15%-14.18%+5.78%+12.74%SNDXSyndax Pharmaceuticals0.00%-1.43%-5.05%+1.27%+87.23%VCELVericel0.00%+5.15%+0.96%-8.82%-15.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITOSiTeos Therapeutics$10.15$10.14$6.18▼$11.35$448.73M1.311.57 million shsN/AOCULOcular Therapeutix$8.23+0.1%$8.81$6.23▼$16.44$1.80B0.932.89 million shs2.03 million shsSNDXSyndax Pharmaceuticals$19.94+0.9%$22.64$8.59▼$25.59$1.77B0.411.78 million shs1.15 million shsVCELVericel$34.73-1.2%$33.72$28.95▼$45.97$1.77B1.15710,587 shs383,195 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITOSiTeos Therapeutics0.00%0.00%0.00%0.00%+23.48%OCULOcular Therapeutix0.00%-10.15%-14.18%+5.78%+12.74%SNDXSyndax Pharmaceuticals0.00%-1.43%-5.05%+1.27%+87.23%VCELVericel0.00%+5.15%+0.96%-8.82%-15.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITOSiTeos Therapeutics 2.33Hold$10.755.91% UpsideOCULOcular Therapeutix 2.79Moderate Buy$23.78188.92% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55113.37% UpsideVCELVericel 2.50Moderate Buy$55.4059.52% UpsideCurrent Analyst Ratings BreakdownLatest ITOS, VCEL, OCUL, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/13/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $37.005/11/2026VCELVericel Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026VCELVericel HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.005/6/2026OCULOcular Therapeutix Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$30.005/5/2026OCULOcular Therapeutix Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/21/2026OCULOcular Therapeutix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026VCELVericel Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$48.00 ➝ $42.004/13/2026OCULOcular Therapeutix HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.004/1/2026SNDXSyndax Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $34.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91OCULOcular Therapeutix$51.95M34.69N/AN/A$2.66 per share3.09SNDXSyndax Pharmaceuticals$172.35M10.25N/AN/A$0.47 per share42.43VCELVericel$276.26M6.42$0.56 per share62.52$6.98 per share4.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%N/AOCULOcular Therapeutix-$265.94M-$1.46N/AN/AN/A-558.24%-64.28%-48.15%8/4/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)VCELVericel$16.52M$0.4282.6941.84N/A7.35%6.41%4.61%7/30/2026 (Estimated)Latest ITOS, VCEL, OCUL, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026VCELVericel-$0.15-$0.12+$0.03-$0.12$63.68 million$68.43 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million2/26/2026Q4 2025SNDXSyndax Pharmaceuticals-$0.64-$0.78-$0.14-$0.78$64.75 million$68.73 million2/26/2026Q4 2025VCELVericel$0.45$0.45N/A$0.45$92.66 million$92.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthITOSiTeos TherapeuticsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITOSiTeos TherapeuticsN/A7.537.53OCULOcular Therapeutix0.1214.8114.73SNDXSyndax Pharmaceuticals8.265.475.06VCELVericelN/A5.184.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITOSiTeos Therapeutics97.16%OCULOcular Therapeutix59.21%SNDXSyndax PharmaceuticalsN/AVCELVericelN/AInsider OwnershipCompanyInsider OwnershipITOSiTeos Therapeutics14.20%OCULOcular Therapeutix2.30%SNDXSyndax Pharmaceuticals4.10%VCELVericel7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionableOCULOcular Therapeutix230218.96 million213.92 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableVCELVericel30051.07 million47.19 millionOptionableITOS, VCEL, OCUL, and SNDX HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 23 at 4:49 AM | americanbankingnews.comSummit Creek Advisors LLC Reduces Stock Position in Vericel Corporation $VCELMay 21 at 7:28 AM | marketbeat.comVericel Lifts 2026 Outlook After Standout QuarterMay 19, 2026 | tipranks.comVericel Corporation $VCEL Stock Position Reduced by Truist Financial CorpMay 18, 2026 | marketbeat.comVericel (NASDAQ:VCEL) Rating Lowered to Hold at Wall Street ZenMay 16, 2026 | americanbankingnews.comWhat is HC Wainwright's Estimate for Vericel Q4 Earnings?May 11, 2026 | marketbeat.comVericel Corporation 2026 Q1 - Results - Earnings Call PresentationMay 9, 2026 | seekingalpha.comAnalysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter ReportMay 9, 2026 | finance.yahoo.comVericel (VCEL) Q1 2026 Earnings TranscriptMay 9, 2026 | finance.yahoo.comVericel Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comVericel Earnings Call Signals Accelerating Growth and MarginsMay 8, 2026 | tipranks.comVericel (NASDAQ:VCEL) Trading Down 9.1% - What's Next?May 8, 2026 | marketbeat.comVericel Corporation (VCEL) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comVericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPSMay 7, 2026 | marketbeat.comVericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue EstimatesMay 7, 2026 | zacks.comVericel (NASDAQ:VCEL) Shares Gap Up on Strong EarningsMay 7, 2026 | marketbeat.comVericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 MillionMay 7, 2026 | quiverquant.comQVericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial GuidanceMay 7, 2026 | globenewswire.comVericel Q1 2026 earnings previewMay 7, 2026 | msn.comWall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a BetMay 4, 2026 | zacks.comVericel Shareholders Reaffirm Board, Pay Plan, AuditorMay 1, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITOS, VCEL, OCUL, and SNDX Company DescriptionsiTeos Therapeutics NASDAQ:ITOSiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Ocular Therapeutix NASDAQ:OCUL$8.23 +0.01 (+0.12%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$8.30 +0.07 (+0.84%) As of 05/22/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Syndax Pharmaceuticals NASDAQ:SNDX$19.94 +0.17 (+0.86%) As of 05/22/2026 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Vericel NASDAQ:VCEL$34.73 -0.42 (-1.19%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$34.74 +0.01 (+0.01%) As of 05/22/2026 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
